FCGRT, a cancer-derived immunoglobulin G binding protein, mediates the malignant phenotype of glioma

Abstract

Abstract CIgG (cancer-derived immunoglobulin G) has received increasing attention, and was first discovered by our group to indicate poor prognosis in glioma. Furthermore, by protein mass spectrometry, we found that Fc gamma receptor and transporter (FCGRT) can combine with CIgG. However, the study of FCGRT in glioma has not been reported. We used the CGGA325 dataset to verify the importance of FCGRT on the prognosis of glioma patients. We found that patients with higher FCGRT expression had a shorter overall survival; survival stratification analysis also showed that the effect of FCGRT on survival was unaffected by the clinical characteristics of patients. Immunohistochemistry results also confirmed that FCGRT expression was closely related to the prognosis of gliomas. Taken together, this suggests that FCGRT could be an independent prognostic marker for glioma patients. Similar conclusions were obtained from TCGA as a validation cohort. Single cell sequencing data analysis showed that FCGRT was mainly enriched in monocytes and macrophages, suggesting that FCGRT could play a role in the microenvironment of glioma. Estimate, ssGSEA, EPIC and xCell were used for immune infiltration analysis. These results showed that FCGRT was closely related to the tumor microenvironment, especially to macrophages in the tumor microenvironment (r = 0.743, p < 0.001). We then used immune related genes to perform KNM clustering on the CGGA325 dataset, which were divided into cluster1 and cluster2. These two types of patients had significant differences in prognosis. Interestingly we also found that FCGRT was significantly increased in cluster1 with poor prognosis, and was positively correlated with IGHG1. Therefore, we believe that FCGRT is an independent prognostic factor for glioma patients.